Walleye Capital LLC Invests $274,000 in Electromed, Inc. (NYSE:ELMD)

Walleye Capital LLC acquired a new stake in shares of Electromed, Inc. (NYSE:ELMD) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,767 shares of the company’s stock, valued at approximately $274,000. Walleye Capital LLC owned 0.15% of Electromed at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ELMD. Pekin Hardy Strauss Inc. acquired a new stake in shares of Electromed during the second quarter worth $522,000. Navellier & Associates Inc. acquired a new position in shares of Electromed during the 3rd quarter worth about $368,000. Marshall Wace LLP acquired a new position in Electromed in the 2nd quarter valued at approximately $256,000. Hunter Associates Investment Management LLC grew its stake in shares of Electromed by 12.3% in the 3rd quarter. Hunter Associates Investment Management LLC now owns 102,450 shares of the company’s stock valued at $2,199,000 after purchasing an additional 11,250 shares during the period. Finally, Morgan Dempsey Capital Management LLC bought a new stake in shares of Electromed in the 2nd quarter valued at approximately $108,000. Institutional investors and hedge funds own 40.82% of the company’s stock.

Electromed Price Performance

NYSE ELMD opened at $29.09 on Wednesday. The firm has a market cap of $246.10 million, a PE ratio of 40.40 and a beta of 0.28. Electromed, Inc. has a one year low of $9.81 and a one year high of $31.31. The stock’s 50 day simple moving average is $25.60 and its 200 day simple moving average is $19.31.

Electromed (NYSE:ELMD) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.13. The company had revenue of $14.67 million for the quarter. Electromed had a return on equity of 15.32% and a net margin of 11.34%.

Insider Buying and Selling

In other news, Director Andrew Summers sold 12,731 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $29.98, for a total value of $381,675.38. Following the completion of the transaction, the director now owns 165,755 shares in the company, valued at $4,969,334.90. This trade represents a 7.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 14.00% of the stock is currently owned by company insiders.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.